Logo image of ELVN

ENLIVEN THERAPEUTICS INC (ELVN) Stock Fundamental Analysis

NASDAQ:ELVN - Nasdaq - US29337E1029 - Common Stock - Currency: USD

20.22  +0.45 (+2.28%)

After market: 20.22 0 (0%)

Fundamental Rating

3

ELVN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ELVN as it has an excellent financial health rating, but there are worries on the profitability. ELVN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ELVN had negative earnings in the past year.
In the past year ELVN has reported a negative cash flow from operations.
In the past 5 years ELVN reported 4 times negative net income.
ELVN had a negative operating cash flow in each of the past 5 years.
ELVN Yearly Net Income VS EBIT VS OCF VS FCFELVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

ELVN's Return On Assets of -31.34% is in line compared to the rest of the industry. ELVN outperforms 52.33% of its industry peers.
ELVN's Return On Equity of -32.89% is fine compared to the rest of the industry. ELVN outperforms 62.69% of its industry peers.
Industry RankSector Rank
ROA -31.34%
ROE -32.89%
ROIC N/A
ROA(3y)-17.29%
ROA(5y)-32.18%
ROE(3y)-18.6%
ROE(5y)-34.76%
ROIC(3y)N/A
ROIC(5y)N/A
ELVN Yearly ROA, ROE, ROICELVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ELVN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELVN Yearly Profit, Operating, Gross MarginsELVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

ELVN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ELVN has more shares outstanding
There is no outstanding debt for ELVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ELVN Yearly Shares OutstandingELVN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ELVN Yearly Total Debt VS Total AssetsELVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 46.38 indicates that ELVN is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 46.38, ELVN belongs to the best of the industry, outperforming 96.89% of the companies in the same industry.
There is no outstanding debt for ELVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 46.38
ROIC/WACCN/A
WACCN/A
ELVN Yearly LT Debt VS Equity VS FCFELVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

ELVN has a Current Ratio of 21.06. This indicates that ELVN is financially healthy and has no problem in meeting its short term obligations.
ELVN has a Current ratio of 21.06. This is amongst the best in the industry. ELVN outperforms 92.75% of its industry peers.
ELVN has a Quick Ratio of 21.06. This indicates that ELVN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 21.06, ELVN belongs to the best of the industry, outperforming 92.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 21.06
Quick Ratio 21.06
ELVN Yearly Current Assets VS Current LiabilitesELVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

ELVN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.52%.
EPS 1Y (TTM)0.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 4.29% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-14.53%
EPS Next 2Y-17.14%
EPS Next 3Y-20.94%
EPS Next 5Y4.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELVN Yearly Revenue VS EstimatesELVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ELVN Yearly EPS VS EstimatesELVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ELVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELVN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELVN Price Earnings VS Forward Price EarningsELVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELVN Per share dataELVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as ELVN's earnings are expected to decrease with -20.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.14%
EPS Next 3Y-20.94%

More info and screens

0

5. Dividend

5.1 Amount

ELVN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENLIVEN THERAPEUTICS INC

NASDAQ:ELVN (8/15/2025, 6:21:36 PM)

After market: 20.22 0 (0%)

20.22

+0.45 (+2.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07
Earnings (Next)11-11 2025-11-11
Inst Owners77.19%
Inst Owner Change1.06%
Ins Owners4.12%
Ins Owner Change3.69%
Market Cap1.16B
Analysts85.33
Price Target41.82 (106.82%)
Short Float %11.93%
Short Ratio10.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.38%
Min EPS beat(2)-10.75%
Max EPS beat(2)13.51%
EPS beat(4)3
Avg EPS beat(4)8.76%
Min EPS beat(4)-10.75%
Max EPS beat(4)27.01%
EPS beat(8)5
Avg EPS beat(8)4.83%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.18%
PT rev (3m)7.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.79%
EPS NY rev (1m)0%
EPS NY rev (3m)4.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-28.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.03
P/tB 4.03
EV/EBITDA N/A
EPS(TTM)-1.92
EYN/A
EPS(NY)-2.59
Fwd EYN/A
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0
BVpS5.02
TBVpS5.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.34%
ROE -32.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.29%
ROA(5y)-32.18%
ROE(3y)-18.6%
ROE(5y)-34.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.06
Quick Ratio 21.06
Altman-Z 46.38
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)41.02%
Cap/Depr(5y)30.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.56%
EPS Next Y-14.53%
EPS Next 2Y-17.14%
EPS Next 3Y-20.94%
EPS Next 5Y4.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.59%
EBIT Next 3Y-35.57%
EBIT Next 5YN/A
FCF growth 1Y-60%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.6%
OCF growth 3YN/A
OCF growth 5YN/A